Tyler Van Buren is ranked #1759 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Tyler Van Buren

Tyler Van Buren

Q: How accurate are Tyler Van Buren's stock ratings?

About 58% of Tyler's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, measured by 13Foresight from historical prices.

TD Cowen

Wall Street Analyst

★★★☆☆

#1759

on 13Foresight · ranked by our own returns

58%

Success Rate

-0.9%

Average Return

48 of 83 calls profitable · +0.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 58% of Tyler Van Buren's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

195 Buy 29 Hold 0 Sell

Tyler's Stock Coverage 65 ratings · 2026-08-08

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ARTV Artiva Biotherapeutics, Inc.	Aug 07, 2026	BUY	Strong Buy +165.6% avg upside 7 analysts	$11.58 2.76% Upside	+0.0%	·
OBX Obsidian Therapeutics	Aug 06, 2026	BUY	Buy -62.0% avg upside 9 analysts	—	·	·
RNAC Cartesian Therapeutics	Aug 06, 2026	BUY	Strong Buy +258.4% avg upside 19 analysts	—	+0.5%	·
IOVA Iovance Biotherapeutics	Aug 06, 2026	BUY	Buy +108.7% avg upside 24 analysts	$7.00 10.47% Upside	·	·
GILD Gilead Sciences	Aug 05, 2026	BUY	Strong Buy -10.6% avg upside 66 analysts	$160.00 20.05% Upside	+1.1%	·
ARQT Arcutis Biotherapeutics	Aug 05, 2026	BUY	Strong Buy +57.2% avg upside 14 analysts	$35.00 38.46% Upside	-5.5%	·
TVTX Travere Therapeutics	Aug 04, 2026	BUY	Strong Buy -9.0% avg upside 22 analysts	$75.00 22.35% Upside	+12.0%	·
CRSP Crispr Therapeutics AG	Aug 03, 2026	HOLD	Buy +43.2% avg upside 41 analysts	$45.00 15.98% Downside	+8.1%	·
MRNA Moderna	Jul 31, 2026	HOLD	Hold +21.2% avg upside 38 analysts	$40.00 32.34% Downside	+7.9%	·
REGN Regeneron	Jul 30, 2026	BUY	Strong Buy +0.1% avg upside 58 analysts	$960.00 22.45% Upside	+6.2%	·
SMMT Summit Therapeutics	Jul 27, 2026	BUY	Strong Buy +105.6% avg upside 27 analysts	—	+3.3%	·
CRNX Crinetics Pharmaceuticals	Jul 07, 2026	HOLD	Buy -7.8% avg upside 21 analysts	—	-0.1%	·
APGE Apogee Therapeutics	Jun 24, 2026	HOLD	Buy -8.0% avg upside 19 analysts	—	+1.4%	·
ABBV AbbVie	Jun 23, 2026	BUY	Strong Buy -3.0% avg upside 46 analysts	$280.00 13.90% Upside	+5.5%	·
SYRE Spyre Therapeutics	Jun 23, 2026	BUY	Strong Buy -12.8% avg upside 23 analysts	—	+8.1%	·
ODTX Odyssey Therapeutics, Inc.	Jun 18, 2026	BUY	Strong Buy +49.6% avg upside 5 analysts	—	+11.0%	·
ALLO Allogene Therapeutics	May 13, 2026	BUY	Strong Buy +663.0% avg upside 28 analysts	—	-17.0%	·
TYRA Tyra Bioscience	May 13, 2026	BUY	Strong Buy +69.0% avg upside 17 analysts	—	-26.8%	·
ORKA Oruka Therapeutics	May 13, 2026	BUY	Strong Buy +18.3% avg upside 16 analysts	—	+56.4%	·
ZNTL Zentalis Pharmaceuticals	May 12, 2026	BUY	Buy +230.5% avg upside 18 analysts	—	+10.8%	·
MAZE Maze Therapeutics, Inc.	May 12, 2026	BUY	Strong Buy +120.0% avg upside 12 analysts	—	+11.1%	·
OLMA Olema Pharmaceuticals	May 12, 2026	BUY	Strong Buy +218.5% avg upside 16 analysts	—	-13.7%	·
CCCC C4 Therapeutics	May 12, 2026	BUY	Strong Buy +381.1% avg upside 19 analysts	—	+13.9%	·
IMNM Immunome	May 12, 2026	BUY	Strong Buy +33.2% avg upside 16 analysts	—	+0.2%	·
ARVN Arvinas Holding Company	May 12, 2026	HOLD	Buy +233.5% avg upside 28 analysts	—	-12.2%	·
BCAX Bicara Therapeutics Inc.	May 11, 2026	BUY	Strong Buy +11.8% avg upside 14 analysts	—	+22.4%	·
AKTS Aktis Oncology, Inc.	May 11, 2026	BUY	Strong Buy +32.6% avg upside 9 analysts	—	+32.1%	·
CGON CG Oncology, Inc.	May 11, 2026	BUY	Strong Buy +14.5% avg upside 17 analysts	—	+7.6%	·
JBIO Jade Biosciences	May 08, 2026	BUY	Strong Buy +159.1% avg upside 16 analysts	—	-13.8%	·
TECX Tectonic Therapeutic	May 08, 2026	BUY	Strong Buy +82.5% avg upside 24 analysts	—	+6.8%	·
BBIO BridgeBio Pharma	May 07, 2026	BUY	Strong Buy +10.2% avg upside 34 analysts	$95.00 12.38% Upside	+22.8%	·
NAMS NewAmsterdam Pharma Company	May 07, 2026	BUY	Strong Buy +70.7% avg upside 19 analysts	—	-20.3%	·
MBX MBX Biosciences, Inc.	May 07, 2026	BUY	Strong Buy +14.0% avg upside 14 analysts	—	+95.4%	·
IMCR Immunocore Holdings	May 06, 2026	BUY	Strong Buy +88.9% avg upside 22 analysts	$60.00 76.39% Upside	+10.6%	·
IDYA IDEAYA Biosciences	May 05, 2026	BUY	Strong Buy +32.1% avg upside 29 analysts	—	+25.8%	·
BHVN Biohaven Ltd.	May 04, 2026	BUY	Buy +56.1% avg upside 25 analysts	$30.00 104.61% Upside	+42.2%	·
EYPT EyePoint Pharmaceuticals	Nov 05, 2025	BUY	Strong Buy +143.9% avg upside 20 analysts	$20.00 43.95% Upside	+26.0%	·
KROS Keros Therapeutics	Nov 05, 2025	HOLD	Strong Buy +117.5% avg upside 21 analysts	—	-36.1%	·
RCKT Rocket Pharmaceuticals	Aug 08, 2025	HOLD	Buy +357.2% avg upside 29 analysts	—	+22.0%	·
FATE Fate Therapeutics	Nov 08, 2023	HOLD	Buy +343.8% avg upside 31 analysts	—	+3.9%	·
ALGS Aligos Therapeutics	Mar 11, 2022	BUY	Strong Buy +728.1% avg upside 11 analysts	$15.00 168.40% Upside	-49.0%	·
ONC BeOne Medicines	Oct 01, 2021	HOLD	Strong Buy +4.0% avg upside 28 analysts	—	-62.2%	·
KURA Kura Oncology	Oct 01, 2021	HOLD	Strong Buy +172.3% avg upside 26 analysts	—	-28.6%	·
OCUL Ocular Therapeutix	Oct 01, 2021	HOLD	Strong Buy +169.6% avg upside 21 analysts	—	-60.0%	·
TBPH Theravance Biopharma	Oct 01, 2021	HOLD	Buy +9.0% avg upside 18 analysts	—	+36.3%	·
PLRX Pliant Therapeutics	Oct 01, 2021	HOLD	Buy +2027.4% avg upside 21 analysts	—	+21.0%	·
PRAX Praxis Precision Medicines	Oct 01, 2021	HOLD	Strong Buy +50.2% avg upside 24 analysts	—	-88.2%	·
NRIX Nurix Therapeutics	Oct 01, 2021	HOLD	Strong Buy +26.2% avg upside 28 analysts	—	-58.3%	·
AMRX Amneal Pharmaceuticals	Oct 01, 2021	HOLD	Strong Buy -2.3% avg upside 18 analysts	—	-63.5%	·
AGIO Agios Pharma	Oct 01, 2021	HOLD	Strong Buy +89.3% avg upside 29 analysts	—	-39.0%	·
INVA Innoviva	Oct 01, 2021	HOLD	Buy +39.9% avg upside 12 analysts	—	-31.8%	·
TEVA Teva Pharmaceutical	Oct 01, 2021	HOLD	Buy -14.9% avg upside 39 analysts	—	-16.8%	·
GYRE Gyre Therapeutics	Oct 01, 2021	HOLD	Strong Buy +214.7% avg upside 15 analysts	—	-53.1%	·
NKTR Nektar Therapeutics	Oct 01, 2021	HOLD	Buy -1.2% avg upside 26 analysts	—	-82.6%	·
IONS Ionis Pharmaceuticals	Oct 01, 2021	HOLD	Strong Buy +41.3% avg upside 43 analysts	—	+31.8%	·
INCY Incyte	Oct 01, 2021	HOLD	Buy -10.5% avg upside 47 analysts	—	-2.3%	·
GSK GlaxoSmithKline	Oct 01, 2021	HOLD	Hold -17.6% avg upside 19 analysts	—	-19.2%	·
APOG Apogee	Oct 01, 2021	HOLD	Strong Buy +4.1% avg upside 7 analysts	—	+1.3%	·
BCRX BioCryst	Oct 01, 2021	HOLD	Strong Buy +93.4% avg upside 24 analysts	—	-8.2%	·
NGNE Neurogene	Oct 01, 2021	HOLD	Buy +39.4% avg upside 23 analysts	—	-91.2%	·
SRPT Sarepta Therapeutics	Oct 01, 2021	HOLD	Buy +255.4% avg upside 49 analysts	—	+15.1%	·
GOSS Gossamer Bio	Oct 01, 2021	HOLD	Buy +3710.8% avg upside 17 analysts	—	·	·
MGTX Meiragtx Holdings	Oct 01, 2021	HOLD	Strong Buy +99.4% avg upside 13 analysts	—	-36.8%	·
OVID Ovid Therapeutics	Oct 01, 2021	HOLD	Strong Buy +92.0% avg upside 18 analysts	—	-47.9%	·
CYPH Cypherpunk Technologies	Oct 01, 2021	HOLD	Buy +1174.2% avg upside 9 analysts	—	·	·

🔒 60 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Tyler Van Buren — Frequently Asked Questions

How accurate are Tyler Van Buren's stock ratings?

Based on the calls 13Foresight could measure, about 58% of Tyler's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, or +0.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Tyler ranked on 13Foresight?

Tyler Van Buren is currently ranked #1759 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Tyler cover?

Tyler most recently has ratings on ARTV, OBX, RNAC, IOVA, GILD, ARQT, TVTX, CRSP, MRNA, REGN, SMMT, CRNX and 53 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Tyler Van Buren

Rating Distribution

Welcome to 13Foresight!